Linezolid is a synthetic antibiotic belonging to the oxazolidinone class, developed to combat serious Gram-positive bacterial infections, including resistant strains such as MRSA and VRE, and it works by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit. It was developed in the 1990s by Pharmacia & Upjohn (later becoming part of Pfizer) as part of a research effort to create new agents effective against multidrug-resistant pathogens at a time when existing antibiotic options were becoming less effective. Linezolid was first approved by the U.S. FDA in 2000 and subsequently introduced into global clinical use as one of the first fully synthetic antibiotics in its class, marking a significant milestone in antimicrobial therapy due to its oral and intravenous availability and its effectiveness against resistant hospital-acquired infections.
